Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.

Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D.

EMBO Mol Med. 2016 May 6. pii: e201505869. doi: 10.15252/emmm.201505869. [Epub ahead of print]

2.

HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID mice.

Wu C, Cao X, Yu D, Huijbers EJ, Essand M, Akusjärvi G, Johansson S, Svensson C.

Virology. 2016 Feb;489:44-50. doi: 10.1016/j.virol.2015.11.031. Epub 2015 Dec 18.

PMID:
26707269
3.

Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas.

Zhang L, Kundu S, Feenstra T, Li X, Jin C, Laaniste L, El Hassan TE, Ohlin KE, Yu D, Olofsson T, Olsson AK, Pontén F, Magnusson PU, Nilsson KF, Essand M, Smits A, Dieterich LC, Dimberg A.

Sci Signal. 2015 Dec 8;8(406):ra125. doi: 10.1126/scisignal.aaa1690.

PMID:
26645582
4.

Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model.

Fransson M, Brännström J, Duprez I, Essand M, Le Blanc K, Korsgren O, Magnusson PU.

Regen Med Res. 2015 Sep 30;3:1. doi: 10.1186/s40340-015-0010-9. eCollection 2015.

5.

Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.

Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan TE, Georganaki M, Bazzar W, Lööf J, Trendelenburg G, Essand M, Pontén F, Smits A, Dimberg A.

Cancer Res. 2015 Nov 1;75(21):4504-16. doi: 10.1158/0008-5472.CAN-14-3636. Epub 2015 Sep 11.

PMID:
26363010
6.

Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy.

Giandomenico V, Thirlwell C, Essand M.

Front Horm Res. 2015;44:248-62. doi: 10.1159/000403885. Epub 2015 Aug 14.

PMID:
26303717
7.

Correction: Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration.

Ramachandran M, Jin C, Yu D, Eriksson F, Essand M.

J Immunol. 2015 Jun 1;194(11):5568. doi: 10.4049/jimmunol.1500649. No abstract available.

PMID:
25980031
8.

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Hillerdal V, Essand M.

BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. Review.

9.

Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration.

Ramachandran M, Jin C, Yu D, Eriksson F, Essand M.

J Immunol. 2014 Sep 1;193(5):2287-96. doi: 10.4049/jimmunol.1400339. Epub 2014 Jul 21. Erratum in: J Immunol. 2015 Jun 1;194(11):5568.

10.

Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland NJ, Bangma CH.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):7-15. doi: 10.1089/humc.2013.181.

PMID:
24649837
11.

A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells.

Liljenfeldt L, Yu D, Chen L, Essand M, Mangsbo SM.

J Immunother. 2014 Apr;37(3):155-62. doi: 10.1097/CJI.0000000000000028.

PMID:
24598450
12.

Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland N, Bangma CH.

Hum Gene Ther Clin Dev. 2014 Feb 18. [Epub ahead of print]

PMID:
24548052
13.

Immunological shielding by induced recruitment of regulatory T-lymphocytes delays rejection of islets transplanted in muscle.

Vågesjö E, Christoffersson G, Waldén TB, Carlsson PO, Essand M, Korsgren O, Phillipson M.

Cell Transplant. 2015;24(2):263-76. doi: 10.3727/096368914X678535. Epub 2014 Jan 29.

PMID:
24480306
14.

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.

15.

Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors.

Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M.

Mol Ther Methods Clin Dev. 2014 Mar 5;1:14001. doi: 10.1038/mtm.2014.1. eCollection 2014.

16.

Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Jin C, Yu D, Čančer M, Nilsson B, Leja J, Essand M.

Hum Gene Ther. 2013 Aug;24(8):766-75. doi: 10.1089/hum.2012.132.

17.

An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.

Ramachandran M, Yu D, Wanders A, Essand M, Eriksson F.

Mol Ther. 2013 Nov;21(11):2008-18. doi: 10.1038/mt.2013.153. Epub 2013 Jul 2.

18.

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

Karlsson H, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, Nilsson K, Frisk P, Jernberg-Wiklund H, Loskog A.

Cancer Gene Ther. 2013 Jul;20(7):386-93. doi: 10.1038/cgt.2013.35. Epub 2013 Jun 21. Erratum in: Cancer Gene Ther. 2013 Dec;20(12):702. Karlsson, S C H [corrected to Karlsson, H];Loskog, S I A [corrected to Loskog, A].

PMID:
23788110
19.

Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.

Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O, Le Blanc K, Uhrbom L, Forsberg-Nilsson K, Westermark B, Adamson R, Maitland N, Fan X, Essand M.

PLoS One. 2013;8(1):e54952. doi: 10.1371/journal.pone.0054952. Epub 2013 Jan 25.

20.

Genetically engineered T cells for the treatment of cancer.

Essand M, Loskog AS.

J Intern Med. 2013 Feb;273(2):166-81. doi: 10.1111/joim.12020. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk